{"id":"estrogen-therapy","safety":{"commonSideEffects":[{"rate":"10–20%","effect":"Breast tenderness"},{"rate":"5–15%","effect":"Vaginal bleeding or spotting"},{"rate":"5–10%","effect":"Headache"},{"rate":"5–10%","effect":"Nausea"},{"rate":"5–10%","effect":"Fluid retention"},{"rate":"1–3%","effect":"Increased risk of venous thromboembolism"},{"rate":null,"effect":"Increased risk of breast cancer (with long-term use)"},{"rate":null,"effect":"Increased risk of endometrial cancer (unopposed estrogen)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Estrogen acts as a ligand for nuclear estrogen receptors, modulating gene transcription and cellular signaling pathways. This restores physiological estrogen levels in postmenopausal women or those with estrogen deficiency, alleviating vasomotor symptoms, supporting bone density, and maintaining cardiovascular and urogenital health.","oneSentence":"Estrogen therapy replaces or supplements endogenous estrogen by binding to estrogen receptors (ERα and ERβ) throughout the body to restore hormonal balance.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:45:54.729Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Vasomotor symptoms (hot flashes, night sweats) in postmenopausal women"},{"name":"Moderate to severe vulvovaginal atrophy"},{"name":"Osteoporosis prevention in postmenopausal women"},{"name":"Estrogen deficiency states"}]},"trialDetails":[{"nctId":"NCT04052555","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-24","conditions":"Bilateral Breast Carcinoma, HER2-Negative Breast Carcinoma, Localized Breast Carcinoma","enrollment":42},{"nctId":"NCT01327781","phase":"PHASE1","title":"Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-03-25","conditions":"HER2/Neu Positive, Recurrent Breast Carcinoma, Stage IIIC Breast Cancer AJCC v7","enrollment":62},{"nctId":"NCT06492616","phase":"PHASE3","title":"A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence","status":"RECRUITING","sponsor":"Stemline Therapeutics, Inc.","startDate":"2024-09-27","conditions":"Breast Cancer","enrollment":4220},{"nctId":"NCT07496294","phase":"NA","title":"Comparison of Oral Dydrogesterone and Vaginal Progesterone in Menopausal Hormone Therapy","status":"NOT_YET_RECRUITING","sponsor":"Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital","startDate":"2026-04","conditions":"Menopausal Women, Menopausal Symptom Relief, Hormone Therapy","enrollment":200},{"nctId":"NCT06998407","phase":"PHASE1, PHASE2","title":"ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Avenzo Therapeutics, Inc.","startDate":"2025-08-20","conditions":"HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer","enrollment":380},{"nctId":"NCT06428396","phase":"PHASE2","title":"Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-11-27","conditions":"Metastatic Breast Cancer","enrollment":120},{"nctId":"NCT06851754","phase":"PHASE3","title":"Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency","status":"RECRUITING","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2025-07-17","conditions":"Premature Ovarian Insufficiency","enrollment":185},{"nctId":"NCT07462663","phase":"","title":"SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Hospital Universitari de Bellvitge","startDate":"2026-05","conditions":"Endometrial Cancer, Endometrial Cancer Stage I, Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I","enrollment":82},{"nctId":"NCT05030038","phase":"","title":"Oral Aromatase Inhibitors Modify the Gut Microbiome","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2022-03-29","conditions":"Breast Cancer","enrollment":25},{"nctId":"NCT02654119","phase":"PHASE2","title":"Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2015-12-11","conditions":"HER2 Positive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7","enrollment":20},{"nctId":"NCT07340541","phase":"PHASE2","title":"Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies","status":"NOT_YET_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2026-02","conditions":"Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer","enrollment":700},{"nctId":"NCT04576455","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-11-27","conditions":"Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer","enrollment":303},{"nctId":"NCT05515354","phase":"PHASE4","title":"Smoking Cessation and Menstrual Cycle Phase","status":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2022-11-30","conditions":"Nicotine Dependence, Tobacco Smoking, Smoking Cessation","enrollment":1200},{"nctId":"NCT03573648","phase":"PHASE2","title":"Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-11-13","conditions":"Breast Cancer","enrollment":33},{"nctId":"NCT00099437","phase":"PHASE3","title":"Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2005-02-13","conditions":"Breast Cancer","enrollment":736},{"nctId":"NCT05654623","phase":"PHASE3","title":"A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-03-03","conditions":"Advanced Breast Cancer","enrollment":624},{"nctId":"NCT07222267","phase":"PHASE1","title":"An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-12-11","conditions":"Breast Cancer, Advanced Solid Tumor","enrollment":86},{"nctId":"NCT06993844","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Ensem Therapeutics","startDate":"2025-06-10","conditions":"Advanced Solid Tumors, Advanced Breast Cancer","enrollment":233},{"nctId":"NCT00893061","phase":"PHASE3","title":"Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2009-03-16","conditions":"Breast Cancer","enrollment":44},{"nctId":"NCT05309655","phase":"NA","title":"Cardiac Outcomes With Near-Complete Estrogen Deprivation","status":"RECRUITING","sponsor":"Duke University","startDate":"2022-09-02","conditions":"Breast Cancer, Triple Negative Breast Cancer, Cardiovascular Complications","enrollment":90},{"nctId":"NCT06075953","phase":"PHASE2","title":"DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2024-02-17","conditions":"Ductal Carcinoma in Situ","enrollment":400},{"nctId":"NCT04802759","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-06-22","conditions":"Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer","enrollment":316},{"nctId":"NCT07085767","phase":"PHASE3","title":"Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer","status":"RECRUITING","sponsor":"Olema Pharmaceuticals, Inc.","startDate":"2025-11-03","conditions":"Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":1000},{"nctId":"NCT03725436","phase":"PHASE1","title":"ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-01-24","conditions":"Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8","enrollment":28},{"nctId":"NCT06958965","phase":"NA","title":"Resistance Exercise Training on Vascular and Physical Function in Postmenopausal Women","status":"COMPLETED","sponsor":"National Yang Ming Chiao Tung University","startDate":"2025-06-09","conditions":"Postmenopausal Women","enrollment":32},{"nctId":"NCT02515110","phase":"NA","title":"Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2015-08-04","conditions":"Breast Cancer, Node-positive Breast Cancer, Breast Adenocarcinoma","enrollment":137},{"nctId":"NCT06382948","phase":"PHASE3","title":"Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.","status":"RECRUITING","sponsor":"MedSIR","startDate":"2024-12-05","conditions":"Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":240},{"nctId":"NCT07466498","phase":"PHASE2","title":"Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial","status":"NOT_YET_RECRUITING","sponsor":"University of Washington","startDate":"2026-08-01","conditions":"Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":60},{"nctId":"NCT07467772","phase":"PHASE2","title":"Ph 2 Elacestrant in ER Positive Uterine Sarcomas","status":"NOT_YET_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2026-02","conditions":"Uterine Sarcoma, Uterine Leiomyosarcoma, Endometrial Stromal Sarcoma","enrollment":30},{"nctId":"NCT06218303","phase":"PHASE1","title":"Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ","status":"RECRUITING","sponsor":"Finn, Olivera, PhD","startDate":"2024-02-07","conditions":"Ductal Carcinoma in Situ","enrollment":50},{"nctId":"NCT04895358","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-06-18","conditions":"Breast Neoplasms","enrollment":340},{"nctId":"NCT05787470","phase":"","title":"State of Hormones Impact Nociceptive Expression","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2023-03-01","conditions":"Pain, Gender Identity","enrollment":120},{"nctId":"NCT02779855","phase":"PHASE1, PHASE2","title":"Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2017-05-02","conditions":"Breast Cancer, Ductal Carcinoma, Invasive Breast Carcinoma","enrollment":50},{"nctId":"NCT06065748","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-12-11","conditions":"Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer","enrollment":1050},{"nctId":"NCT06975111","phase":"PHASE2, PHASE3","title":"Focusing on the Menopausal Transition to Improve Mid-Life Women's Health","status":"NOT_YET_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2026-03-01","conditions":"Menopause, Menopause Hot Flashes, Menopause Related Conditions","enrollment":200},{"nctId":"NCT07455773","phase":"NA","title":"Experimental Study on the Use of Intrauterine Infusion of Autologous Platelet-rich Plasma (PRGF-IUI) in Patients With Recurrent Implantation Failure and/or Refractory Thin Endometrium","status":"NOT_YET_RECRUITING","sponsor":"Azienda Sanitaria Locale di Asti","startDate":"2026-05-01","conditions":"Recurrent Implantation Failure, Endometrial Receptivity Disorders, Embryo Implantation","enrollment":80},{"nctId":"NCT01349322","phase":"PHASE3","title":"Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Radiation Therapy Oncology Group","startDate":"2011-05-24","conditions":"Breast Cancer","enrollment":2354},{"nctId":"NCT04451746","phase":"NA","title":"The Influence of Combined Oral Contraception on the DEvelopment and progRession of Chronic venoUs diSeases","status":"COMPLETED","sponsor":"Clinic of Phlebology and Laser Surgery, Chelyabinsk, Russia","startDate":"2020-06-24","conditions":"Chronic Venous Diseases","enrollment":116},{"nctId":"NCT05700006","phase":"","title":"Pilot Observational Study Examining the Effect of Endocrine Therapy on Aging","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2022-07-25","conditions":"Breast Neoplasm Female, Arthralgia, Aging","enrollment":94},{"nctId":"NCT05551949","phase":"PHASE4","title":"Preventing Recurrent UTI With Vaginal Estrogen","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2022-01-01","conditions":"Recurrent Urinary Tract Infection, Urinary Tract Infections, Cystitis Recurrent","enrollment":27},{"nctId":"NCT07214662","phase":"PHASE1","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2026-01-13","conditions":"Breast Cancer","enrollment":136},{"nctId":"NCT07450300","phase":"","title":"Assessment of the Feasibility of Frozen Embryo Transfers in a Natural Cycle Among Obese Compared to Non-Obese Patients","status":"COMPLETED","sponsor":"Clinique Mathilde","startDate":"2022-11-01","conditions":"Infertility, Female","enrollment":1831},{"nctId":"NCT02564848","phase":"NA","title":"Safety and Efficacy of Omission of Sentinel Node Biopsy in Patients With Estrogen-Positive Breast Cancer Over Age 65","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2016-01-22","conditions":"Breast Cancer","enrollment":200},{"nctId":"NCT05879926","phase":"PHASE3","title":"Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-08-31","conditions":"Breast Cancer","enrollment":3960},{"nctId":"NCT05768139","phase":"PHASE1, PHASE2","title":"First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2023-04-17","conditions":"Breast Cancer, Solid Tumors, Adult","enrollment":720},{"nctId":"NCT06760637","phase":"PHASE3","title":"Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-01-06","conditions":"Breast Cancer","enrollment":1020},{"nctId":"NCT04288089","phase":"PHASE1","title":"A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Inc.","startDate":"2020-04-01","conditions":"Receptors, Estrogen, Genes, Erbb-2, Breast Neoplasms","enrollment":31},{"nctId":"NCT04270149","phase":"PHASE1","title":"Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Herbert Lyerly","startDate":"2020-09-01","conditions":"Breast Cancer","enrollment":8},{"nctId":"NCT02767661","phase":"PHASE3","title":"Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2017-07-19","conditions":"Breast Cancer","enrollment":263},{"nctId":"NCT05774951","phase":"PHASE3","title":"A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-03-31","conditions":"Breast Cancer, Early Breast Cancer","enrollment":4300},{"nctId":"NCT02778685","phase":"PHASE2","title":"Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2016-09-30","conditions":"Metastatic Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7","enrollment":47},{"nctId":"NCT04059484","phase":"PHASE2","title":"Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-10-22","conditions":"Breast Cancer Metastatic","enrollment":367},{"nctId":"NCT00699751","phase":"PHASE3","title":"A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-06-12","conditions":"Hormone Refractory Prostate Cancer, Bone Metastases","enrollment":921},{"nctId":"NCT04961996","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-08-27","conditions":"Early Breast Cancer","enrollment":4170},{"nctId":"NCT04546009","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-10-09","conditions":"Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer","enrollment":992},{"nctId":"NCT05953090","phase":"NA","title":"VALOR: Vaginal Atrophy & Long-term Observation of Recovery","status":"RECRUITING","sponsor":"Stratpharma AG","startDate":"2023-10-30","conditions":"Atrophic Vaginitis, Vaginal Atrophy, Genitourinary Syndrome of Menopause","enrollment":2000},{"nctId":"NCT07422506","phase":"NA","title":"A Real-World Study Comparing the Efficacy of Different Treatment Regimens for Early Missed Abortion","status":"RECRUITING","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2024-01-01","conditions":"Missed Abortion, Early Pregnancy Failure","enrollment":580},{"nctId":"NCT07423611","phase":"PHASE2","title":"ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-10-01","conditions":"Breast Cancer","enrollment":388},{"nctId":"NCT05672901","phase":"NA","title":"Silicone Gel vs. Estrogen Vaginal Cream for the Management of Genitourinary Syndrome of Menopause","status":"RECRUITING","sponsor":"Stratpharma AG","startDate":"2023-04-04","conditions":"Genitourinary Syndrome of Menopause","enrollment":100},{"nctId":"NCT07421908","phase":"NA","title":"Investigating the Association Between Diagnostic and Therapeutic Management Models and Prognosis of Intrauterine Adhesions Based on a Large-Scale Prospective Cohort Study","status":"RECRUITING","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2025-03-01","conditions":"Intrauterine Adhesion","enrollment":5000},{"nctId":"NCT06127979","phase":"NA","title":"A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-11-06","conditions":"Breast Cancer","enrollment":42},{"nctId":"NCT06440967","phase":"PHASE3","title":"A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2024-07-31","conditions":"Hot Flashes","enrollment":540},{"nctId":"NCT04485013","phase":"PHASE1","title":"TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers","status":"RECRUITING","sponsor":"Tizona Therapeutics, Inc","startDate":"2020-07-14","conditions":"Cancer","enrollment":240},{"nctId":"NCT05317364","phase":"PHASE4","title":"Topical Vaginal Estrogen for Postpartum Obstetric Anal Sphincter Injury Recovery","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2022-07-14","conditions":"Obstetric; Injury Pelvic Floor, Sexual Dysfunction, Anal Incontinence","enrollment":38},{"nctId":"NCT06105632","phase":"PHASE2","title":"A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-01-09","conditions":"Advanced or Metastatic Breast Cancer","enrollment":333},{"nctId":"NCT03332797","phase":"PHASE1","title":"A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2017-11-24","conditions":"Breast Cancer","enrollment":181},{"nctId":"NCT05101564","phase":"PHASE2","title":"Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer","status":"COMPLETED","sponsor":"Jennifer Lee Caswell-Jin","startDate":"2023-03-20","conditions":"Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer","enrollment":19},{"nctId":"NCT07406412","phase":"","title":"Hormonal Regulation of Cardiometabolic Health Study","status":"NOT_YET_RECRUITING","sponsor":"University of Jyvaskyla","startDate":"2026-02-20","conditions":"Menopause Surgical","enrollment":120},{"nctId":"NCT06366347","phase":"PHASE2","title":"ALPINE: Maintenance Letrozole/Abemaciclib","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-09-25","conditions":"Endometrial Cancer, Recurrent Endometrial Cancer, TP53","enrollment":32},{"nctId":"NCT05909397","phase":"PHASE3","title":"Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-08-09","conditions":"Breast Cancer","enrollment":59},{"nctId":"NCT04072952","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arvinas Estrogen Receptor, Inc.","startDate":"2019-08-05","conditions":"Breast Cancer","enrollment":217},{"nctId":"NCT01674140","phase":"PHASE3","title":"S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2013-09-12","conditions":"Breast Cancer","enrollment":1939},{"nctId":"NCT07400419","phase":"NA","title":"Effects of Resistance Exercise Among TGD Individuals Initiating Estrogen-Based Gender-Affirming Hormone Therapy","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-03-01","conditions":"Muscle Mass and Strength","enrollment":60},{"nctId":"NCT00066703","phase":"PHASE3","title":"Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2003-11-03","conditions":"Breast Cancer","enrollment":2672},{"nctId":"NCT06830486","phase":"","title":"Effects of Activity on Diabetes Risk Among Breast Cancer Survivors on Endocrine Therapy (ABIDE)","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2022-02-14","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT04499131","phase":"PHASE4","title":"Impact of Different Doses and Routes of Exogenous Progesterone Administration on Endometrial Receptivity Parameters","status":"COMPLETED","sponsor":"Instituto Valenciano de Infertilidad, IVI VALENCIA","startDate":"2021-12-09","conditions":"Infertility, Female, ENDOMETRIAL RECEPTIVITY","enrollment":109},{"nctId":"NCT05306340","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2022-08-03","conditions":"Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer","enrollment":373},{"nctId":"NCT03505736","phase":"","title":"Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2018-06-21","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8","enrollment":25},{"nctId":"NCT06534125","phase":"NA","title":"Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer","status":"RECRUITING","sponsor":"Emory University","startDate":"2024-12-12","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8","enrollment":150},{"nctId":"NCT04650581","phase":"PHASE3","title":"Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2021-01-27","conditions":"Breast Cancer","enrollment":250},{"nctId":"NCT01984138","phase":"PHASE2","title":"REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Polly A. Niravath, MD","startDate":"2013-09","conditions":"Estrogen Receptor Positive Breast Cancer, Breast Cancer","enrollment":33},{"nctId":"NCT03781063","phase":"PHASE2","title":"Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation","status":"COMPLETED","sponsor":"Sermonix Pharmaceuticals Inc.","startDate":"2019-09-20","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":100},{"nctId":"NCT05573334","phase":"NA","title":"Vaginal Care System for Menopausal Women With Urinary Tract Infections","status":"COMPLETED","sponsor":"Vaginal Biome Science","startDate":"2023-07-10","conditions":"Urinary Tract Infections, Vaginal Flora Imbalance","enrollment":8},{"nctId":"NCT07103603","phase":"NA","title":"MHT and Liver Function in Postmenopausal Women","status":"COMPLETED","sponsor":"Ipek B. Ozcivit Erkan, MD","startDate":"2024-10-30","conditions":"Menopause, Non Alcholic Fatty Liver Disease, Hepatic Steatosis","enrollment":44},{"nctId":"NCT07366632","phase":"PHASE1","title":"A Study of Single Dose of BL0175 in Postmenopausal Women","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Best-Link Bioscience, LLC","startDate":"2026-01-26","conditions":"Postmenopausal Women","enrollment":27},{"nctId":"NCT05183828","phase":"PHASE4","title":"Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2022-01-23","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8","enrollment":68},{"nctId":"NCT04692103","phase":"PHASE2","title":"Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2021-07-10","conditions":"Estrogen Receptor Positive, Primary or Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7","enrollment":2},{"nctId":"NCT02158507","phase":"NA","title":"Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2014-09-04","conditions":"Metastatic Triple Negative Breast Cancer","enrollment":20},{"nctId":"NCT01953588","phase":"PHASE3","title":"Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2014-02-27","conditions":"Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma","enrollment":1473},{"nctId":"NCT07222215","phase":"PHASE2","title":"PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)","status":"RECRUITING","sponsor":"Kristina A. Fanucci","startDate":"2026-01-16","conditions":"Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer, Breast Cancer","enrollment":297},{"nctId":"NCT06353269","phase":"PHASE4","title":"Adherence to Vaginal Estrogen Therapy in Hypoestrogenic Women With Recurrent Urinary Tract Infections","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Irvine","startDate":"2024-06-14","conditions":"Recurrent Urinary Tract Infection, Hypoestrogenism","enrollment":111},{"nctId":"NCT06873971","phase":"NA","title":"Er:YAG Laser Combined With Vaginal Estriol for Genitourinary Syndrome of Menopause","status":"RECRUITING","sponsor":"University of Nove de Julho","startDate":"2025-12-10","conditions":"Genitourinary Syndrome of Menopause","enrollment":60},{"nctId":"NCT06970912","phase":"PHASE2","title":"ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-08-01","conditions":"Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer, Early-Stage Breast Cancer","enrollment":393},{"nctId":"NCT06666439","phase":"","title":"Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA in Metastatic Lobular Breast Cancer","status":"RECRUITING","sponsor":"Julia Foldi","startDate":"2024-12-12","conditions":"Metastatic Invasive Lobular Carcinoma (mILC)","enrollment":20},{"nctId":"NCT04356664","phase":"PHASE2, PHASE3","title":"Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis","status":"RECRUITING","sponsor":"Hopital Foch","startDate":"2021-03-18","conditions":"Endometriosis, Adenomyosis, Infertility, Female","enrollment":180},{"nctId":"NCT07346287","phase":"PHASE4","title":"ASSIST-VLA: Assessment of Symptom-Specific Improvement in Diagnosed Vaginal Atrophy Following Laser Therapy","status":"RECRUITING","sponsor":"Stratpharma AG","startDate":"2025-08-13","conditions":"Vaginal Atrophy, Atrophic Vaginitis, Genitourinary Syndrome of Menopause (GSM)","enrollment":10},{"nctId":"NCT04964934","phase":"PHASE3","title":"Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-06-30","conditions":"ER-Positive HER2-Negative Breast Cancer","enrollment":315},{"nctId":"NCT05296798","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-07-18","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":922},{"nctId":"NCT06001762","phase":"PHASE2","title":"TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2023-10-05","conditions":"Breast Cancer, Early-stage Breast Cancer, High Risk Breast Carcinoma","enrollment":90},{"nctId":"NCT05716516","phase":"PHASE2","title":"STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)","status":"RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2023-05-04","conditions":"Metastatic Breast Cancer","enrollment":36}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"DRUG INEFFECTIVE"},{"count":1,"reaction":"ARTHRITIS"},{"count":1,"reaction":"BACK DISORDER"},{"count":1,"reaction":"CERVICAL MYELOPATHY"},{"count":1,"reaction":"FALL"},{"count":1,"reaction":"FEMUR FRACTURE"},{"count":1,"reaction":"GALLBLADDER DISORDER"},{"count":1,"reaction":"HIP FRACTURE"},{"count":1,"reaction":"INTERVERTEBRAL DISC DEGENERATION"},{"count":1,"reaction":"INTERVERTEBRAL DISC PROTRUSION"}],"_approvalHistory":[],"publicationCount":3914,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["white tablet of cycloprogynova","Norelgesetromin","Ethinyl estradiol"],"phase":"marketed","status":"active","brandName":"estrogen therapy","genericName":"estrogen therapy","companyName":"Beni-Suef University","companyId":"beni-suef-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Estrogen therapy replaces or supplements endogenous estrogen by binding to estrogen receptors (ERα and ERβ) throughout the body to restore hormonal balance. Used for Vasomotor symptoms (hot flashes, night sweats) in postmenopausal women, Moderate to severe vulvovaginal atrophy, Osteoporosis prevention in postmenopausal women.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}